Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Large Molecule Bioanalytical Testing Services Market Outlook (2023 to 2033)

Newly-released Large Molecule Bioanalytical Testing Service industry analysis report by Future Market Insights reveals that global sales of Large Molecule Bioanalytical Testing Market in 2022 were held at US$ 1.3 Billion. With a CAGR of 12.1% from 2023 to 2033, the market is projected to reach US$ 4.7 Billion by 2033. Clinical Phase is expected to generate significant revenue and is projected to grow at a CAGR of 10.9% from 2023 to 2033.

Attribute Details
Global Market Size (2023) US$ 1.5 Billion
Global Market Size (2033) US$ 4.7 Billion
Global Market Size CAGR (2023 to 2033) 12.1%
USA Market Size CAGR (2023 to 2033) 12.3%
Key Companies Profiled
  • Covance
  • IQVIA
  • Syneos Health
  • SGS SA
  • Toxikon
  • Intertek Group plc
  • Pace Analytical Services LLC
  • ICON Plc
  • Charles River Laboratories
  • Thermo Fisher Scientific

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Revenue of Large Molecule Bioanalytical Testing Service from 2018 to 2022 Compared to Demand Outlook for 2023 to 2033

As per the Large Molecule Bioanalytical Testing Service industry research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, market value of the Large Molecule Bioanalytical Testing Service industry increased at around 11.9% CAGR, wherein, countries such as the USA, China, Japan, United kingdom and South Korea held significant share in the global market.

The increase in demand for forward-looking and high-grade large molecule bioanalytical testing services is expected to propel the market forward. Reduced time to market, increased regulatory observation, and a high risk of product failure are a few of the factors driving the demand for large molecule bioanalytical testing services. Owing to this, the Large Molecule Bioanalytical Testing Service market is projected to grow at a CAGR of 12.1% over the coming 10 years.

Because of rising healthcare expenditures, there is a greater need for high-quality care. The demand for analytical testing is developing in response to new pharmaceutical product advancements. Due to increased competition in the healthcare business and rising pricing concerns, many companies are turning to outsourcing services for analytical testing.

The demand for analytical testing has increased as research and development activities for new medication development, combination products, and other complex medicines have increased.

What are the key drivers for Large Molecule Bioanalytical Testing Service revenue?

With the prevalence of HIV, infectious illnesses, and other disorders, the demand for bioanalytical testing services has shot up in the recent past. Furthermore, enhanced government actions to control the spread of infectious diseases like Corona and the Ebola virus are expected to assist the business. As a result, the market is expected to grow throughout the assessment period.

Throughout the projection period, increased research activities and the presence of a vast pipeline of peptides, biologics, and amino acid-based compounds are expected to move the market ahead. Bioanalysis of large molecules also involves the utilization of highly skilled professionals as well as analytical gear and infrastructure.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Region-wise Analysis

Which Region is projected to Offer the Significant Opportunity for Large Molecule Bioanalytical Testing Service?

With a CAGR of 12.3% during the projected period, Large Molecule Bioanalytical Testing Service revenue is expected to grow at a significant pace in North America. Because of the rising frequency of numerous chronic diseases and the growing use of large-molecule medicines as an alternative to small molecules, the United States has the largest market share.

According to the International Diabetic Federation Report 2019, the United States has a diabetic population of 49 million geriatrics, which has resulted in an increase in demand for bioanalysis of new peptide therapies such as glucagon-like peptide 1. As a result, the market is likely to grow throughout the forecast period. Furthermore, the presence of large firms in the region aided market expansion.

Country-wise Analysis

USA Large Molecule Bioanalytical Testing Service Market Analysis

As one of the main production hubs for highly dependable, complicated, and high-end pharmaceuticals, the USA accounted for a significant share of the global market in 2022. The market is likely to be driven by rapid technology improvements and increasing demand for bioanalytical testing services. Furthermore, because of the country's developing healthcare business, biopharmaceutical companies are focusing on the USA market.

United kingdom Large Molecule Bioanalytical Testing Service Market Analysis

The market in the United kingdom is expected to reach a valuation of US$ 180.6 Million by 2033. Growing with a CAGR of 12.9% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of around US$ 127 Million.

Japan Large Molecule Bioanalytical Testing Service Market Analysis

In Japan, the market is expected to grow at a CAGR of 10.8% from 2023 to 2033, reaching around US$ 161 Million by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 104 Million during the forecast period.

South Korea Gastro-retentive Drug Delivery Systems Market Analysis

The market in South Korea is expected to reach a valuation of around US$ 123 Million by 2033, growing at a CAGR of 12.6% from 2023 to 2033. The market in the country is expected to witness an absolute dollar opportunity of around US$ 85 Million.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which Phase of Large Molecule Bioanalytical Testing Services will Generate Significant Revenue in the Market in the Forthcoming years?

The clinical segment is expected to grow at a CAGR of 10.9%. Based on the study phase, the market is segmented into preclinical and clinical. The rising frequency of chronic diseases and the growing demand for clinical trials in developing countries are likely to propel the segment forward.

Which Large Molecule Bioanalytical Testing Services Type will be Most Preferred?

The market through Antidrug Antibodies (ADA) is expected to grow at a CAGR of 11.8% during the forecast period. Large-molecule drug development is aided by ADA assays. Antibodies against large molecule medications, such as antibody or protein therapies, are produced by the immune system. As a result, ADAs can be detected using ADA tests. Patients who create an antibody response will have a variety of reactions, ranging from life-threatening to no clinical implications. This can lead to anaphylactic shock, allergic responses, or autoimmunity, among other things.

Pharmacokinetic expert services are carried out in accordance with GCP specifications as well as international regulatory rules. Moreover, clinical trials for biologics and biosimilars include a trial to measure the concentration of this drug in healthy volunteers.

The ELISA or MSD platform is used to offer this service. A commonly utilized immunoassay for the detection of significant in vitro pharmacokinetic research is ELISA. In line with the chemical construction and principle of operation of drug substances, antibody sensitivity in pharmacokinetic immunoanalysis should always be fixed.

Competitive Analysis

The key players operating in the Large Molecule Bioanalytical Testing Services Market include Covance, IQVIA, Syneos Health, SGS SA, Toxikon, Intertek Group plc, Pace Analytical Services LLC, ICON Plc, Charles River Laboratories, and Thermo Fisher Scientific.

Few of the recent developments of key Large Molecule Bioanalytical Testing Service providers are as follows:

  • In November 2021, Labcorp announced the introduction of a new bioanalytical lab facility in Singapore. This laboratory is an expansion of its central laboratory services and will enable to the expansion of the capabilities of the biomedical ecosystem in Singapore.
  • In February 2021, Nexelis acquired GSK’s Marburg, Germany-based vaccines clinical bioanalytical laboratory for expanding its bioanalytical capabilities.

Similarly, recent developments related to companies in the Large Molecule Bioanalytical Testing Services have been tracked by the team at Future Market Insights, which are available in the full report.

Market Segments Covered in Large Molecule Bioanalytical Testing Service Industry Analysis

By Phase:

  • Preclinical
  • With Antibody
  • Without Antibody
  • Clinical

By Type:

  • Pharmacokinetics
  • ADA
  • Others

By Test Type:

  • ADME
  • PK
  • PD
  • Bioavailability
  • Bioequivalence
  • Other Tests

By Therapeutic Area:

  • Oncology
  • Infectious Diseases
  • Cardiology
  • Neurology
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

Frequently Asked Questions

How Big is the Large Molecule Bioanalytical Testing Services Market?

The market is valued at US$ 1.5 billion in 2023.

What is the Growth Potential of the Market?

The growth potential of the market is 12.1% through 2033.

What is the Forecast CAGR of the South Korea Market?

The South Korea market is expected to expand at a CAGR of 12.6% through 2033.

Who are the Key Market Players?

Covance, IQVIA, and Syneos Health are the top players.

Which is the Go-to Market Strategy?

Key players are introducing new production facilities.

Table of Content

1. Executive Summary | Large Molecule Bioanalytical Testing Services Market

    1.1. Global Market Outlook

    1.2. Summary of Statistics

    1.3. Key Market Characteristics & Attributes

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage

    2.2. Market Definition

3. Market Risks and Trends Assessment

    3.1. Risk Assessment

        3.1.1. COVID-19 Crisis and Impact on Large Molecule Bioanalytical Testing Services

        3.1.2. COVID-19 Impact Benchmark with Previous Crisis

        3.1.3. Impact on Market Value (US$ Million)

        3.1.4. Assessment by Key Countries

        3.1.5. Assessment by Key Market Segments

        3.1.6. Action Points and Recommendation for Suppliers

    3.2. Key Trends Impacting the Market

    3.3. Formulation and Product Development Trends

4. Market Background 

    4.1. Large Molecule Bioanalytical Testing Services Market, by Key Countries

    4.2. Opportunity Assessment (US$ Million)

        4.2.1. Total Available Market

        4.2.2. Serviceable Addressable Market

        4.2.3. Serviceable Obtainable Market

    4.3. Market Scenario Forecast

        4.3.1. Demand in optimistic Scenario

        4.3.2. Demand in Likely Scenario

        4.3.3. Demand in Conservative Scenario

    4.4. Investment Feasibility Analysis

        4.4.1. Investment in Established Markets

            4.4.1.1. In Short Term

            4.4.1.2. In Long Term

        4.4.2. Investment in Emerging Markets

            4.4.2.1. In Short Term

            4.4.2.2. In Long Term

    4.5. Forecast Factors - Relevance & Impact

        4.5.1. Top Companies Historical Growth

        4.5.2. Growth in Automation, By Country

        4.5.3. Large Molecule Bioanalytical Testing Services Adoption Rate, By Country

    4.6. Market Dynamics

        4.6.1. Market Driving Factors and Impact Assessment

        4.6.2. Prominent Market Challenges and Impact Assessment

        4.6.3. Opportunities

        4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors 

    5.1. Manufacturers’ Focus on Low Penetration High Growth Markets

    5.2. Banking on with Segments High Incremental Opportunity

    5.3. Peer Benchmarking

6. Global Demand Analysis 2015 to 2021 and Forecast, 2022 to 2032

    6.1. Historical Market Analysis, 2015 to 2021

    6.2. Current and Future Market Projections, 2022 to 2032

    6.3. Y-o-Y Growth Trend Analysis

7. Global Value Analysis 2015 to 2021 and Forecast, 2022 to 2032

    7.1. Historical Market Value (US$ Million) Analysis, 2015 to 2021

    7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Phase

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Million) Analysis By Phase, 2015 to 2021

    8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Phase, 2022 to 2032

        8.3.1. Preclinical

            8.3.1.1. With Antibody

            8.3.1.2. Without Antibody

        8.3.2. Clinical

    8.4. Market Attractiveness Analysis By Phase

9. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Type

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Million) Analysis By Type, 2015 to 2021

    9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Type, 2022 to 2032

        9.3.1. Pharmacokinetics

        9.3.2. ADA

        9.3.3. Other Types

    9.4. Market Attractiveness Analysis By Type

10. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Test Type

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Million) Analysis By Test Type, 2015 to 2021

    10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Test Type, 2022 to 2032

        10.3.1. ADME

        10.3.2. PK

        10.3.3. PD

        10.3.4. Bioavailability

        10.3.5. Bioequivalence

        10.3.6. Other Test Types

    10.4. Market Attractiveness Analysis By Test Type

11. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Therapeutic Area

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Million) Analysis By Therapeutic Area, 2015 to 2021

    11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Therapeutic Area, 2022 to 2032

        11.3.1. Oncology

        11.3.2. Infectious Diseases

        11.3.3. Cardiology

        11.3.4. Neurology

        11.3.5. Other End-users

    11.4. Market Attractiveness Analysis By Therapeutic Area

12. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region

    12.1. Introduction

    12.2. Historical Market Size (US$ Million) Analysis By Region, 2015 to 2021

    12.3. Current Market Size (US$ Million) & Analysis and Forecast By Region, 2022 to 2032

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. Asia Pacific

        12.3.5. Middle East and Africa (MEA)

    12.4. Market Attractiveness Analysis By Region

13. North America Analysis 2015 to 2021 and Forecast 2022 to 2032

    13.1. Introduction

    13.2. Pricing Analysis

    13.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021

    13.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

        13.4.1. By Country

            13.4.1.1. USA

            13.4.1.2. Canada

            13.4.1.3. Rest of North America

        13.4.2. By Phase

        13.4.3. By Type

        13.4.4. By Therapeutic Area

        13.4.5. By Test Type

    13.5. Market Attractiveness Analysis

        13.5.1. By Country

        13.5.2. By Phase

        13.5.3. By Type

        13.5.4. By Therapeutic Area

        13.5.5. By Test Type

14. Latin America Analysis 2015 to 2021 and Forecast 2022 to 2032

    14.1. Introduction

    14.2. Pricing Analysis

    14.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021

    14.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

        14.4.1. By Country

            14.4.1.1. Brazil

            14.4.1.2. Mexico

            14.4.1.3. Rest of Latin America

        14.4.2. By Phase

        14.4.3. By Type

        14.4.4. By Therapeutic Area

        14.4.5. By Test Type

    14.5. Market Attractiveness Analysis

        14.5.1. By Country

        14.5.2. By Phase

        14.5.3. By Type

        14.5.4. By Therapeutic Area

        14.5.5. By Test Type

15. Europe Analysis 2015 to 2021 and Forecast 2022 to 2032

    15.1. Introduction

    15.2. Pricing Analysis

    15.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021

    15.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

        15.4.1. By Country

            15.4.1.1. Germany

            15.4.1.2. France

            15.4.1.3. United kingdom

            15.4.1.4. Italy

            15.4.1.5. Benelux

            15.4.1.6. Nordic Countries

            15.4.1.7. Rest of Europe

        15.4.2. By Phase

        15.4.3. By Type

        15.4.4. By Therapeutic Area

        15.4.5. By Test Type

    15.5. Market Attractiveness Analysis

        15.5.1. By Country

        15.5.2. By Phase

        15.5.3. By Type

        15.5.4. By Therapeutic Area

        15.5.5. By Test Type

16. Asia Pacific Analysis 2015 to 2021 and Forecast 2022 to 2032

    16.1. Introduction

    16.2. Pricing Analysis

    16.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021

    16.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

        16.4.1. By Country

            16.4.1.1. China

            16.4.1.2. Japan

            16.4.1.3. South Korea

            16.4.1.4. Rest of Asia Pacific

        16.4.2. By Phase

        16.4.3. By Type

        16.4.4. By Therapeutic Area

        16.4.5. By Test Type

    16.5. Market Attractiveness Analysis

        16.5.1. By Country

        16.5.2. By Phase

        16.5.3. By Type

        16.5.4. By Therapeutic Area

        16.5.5. By Test Type

17. Middle East and Africa Analysis 2015 to 2021 and Forecast 2022 to 2032

    17.1. Introduction

    17.2. Pricing Analysis

    17.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021

    17.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

        17.4.1. By Country

            17.4.1.1. GCC Countries

            17.4.1.2. South Africa

            17.4.1.3. Turkey

            17.4.1.4. Rest of Middle East and Africa

        17.4.2. By Phase

        17.4.3. By Type

        17.4.4. By Therapeutic Area

        17.4.5. By Test Type

    17.5. Market Attractiveness Analysis

        17.5.1. By Country

        17.5.2. By Phase

        17.5.3. By Type

        17.5.4. By Therapeutic Area

        17.5.5. By Test Type

18. Key Countries Analysis 2015 to 2021 and Forecast 2022 to 2032

    18.1. Introduction

        18.1.1. Market Value Proportion Analysis, By Key Countries

        18.1.2. Global Vs. Country Growth Comparison

    18.2. US Analysis

        18.2.1. Value Proportion Analysis by Market Taxonomy

        18.2.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.2.2.1. By Phase

            18.2.2.2. By Type

            18.2.2.3. By Therapeutic Area

            18.2.2.4. By Test Type

    18.3. Canada Analysis

        18.3.1. Value Proportion Analysis by Market Taxonomy

        18.3.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.3.2.1. By Phase

            18.3.2.2. By Type

            18.3.2.3. By Therapeutic Area

            18.3.2.4. By Test Type

    18.4. Mexico Analysis

        18.4.1. Value Proportion Analysis by Market Taxonomy

        18.4.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.4.2.1. By Phase

            18.4.2.2. By Type

            18.4.2.3. By Therapeutic Area

            18.4.2.4. By Test Type

    18.5. Brazil Analysis

        18.5.1. Value Proportion Analysis by Market Taxonomy

        18.5.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.5.2.1. By Phase

            18.5.2.2. By Type

            18.5.2.3. By Therapeutic Area

            18.5.2.4. By Test Type

    18.6. Germany Analysis

        18.6.1. Value Proportion Analysis by Market Taxonomy

        18.6.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.6.2.1. By Phase

            18.6.2.2. By Type

            18.6.2.3. By Therapeutic Area

            18.6.2.4. By Test Type

    18.7. France Analysis

        18.7.1. Value Proportion Analysis by Market Taxonomy

        18.7.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.7.2.1. By Phase

            18.7.2.2. By Type

            18.7.2.3. By Therapeutic Area

            18.7.2.4. By Test Type

    18.8. Italy Analysis

        18.8.1. Value Proportion Analysis by Market Taxonomy

        18.8.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.8.2.1. By Phase

            18.8.2.2. By Type

            18.8.2.3. By Therapeutic Area

            18.8.2.4. By Test Type

    18.9. BENELUX Analysis

        18.9.1. Value Proportion Analysis by Market Taxonomy

        18.9.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.9.2.1. By Phase

            18.9.2.2. By Type

            18.9.2.3. By Therapeutic Area

            18.9.2.4. By Test Type

    18.10. UK Analysis

        18.10.1. Value Proportion Analysis by Market Taxonomy

        18.10.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.10.2.1. By Phase

            18.10.2.2. By Type

            18.10.2.3. By Therapeutic Area

            18.10.2.4. By Test Type

    18.11. Nordic Countries Analysis

        18.11.1. Value Proportion Analysis by Market Taxonomy

        18.11.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.11.2.1. By Phase

            18.11.2.2. By Type

            18.11.2.3. By Therapeutic Area

            18.11.2.4. By Test Type

    18.12. China Analysis

        18.12.1. Value Proportion Analysis by Market Taxonomy

        18.12.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.12.2.1. By Phase

            18.12.2.2. By Type

            18.12.2.3. By Therapeutic Area

            18.12.2.4. By Test Type

    18.13. Japan Analysis

        18.13.1. Value Proportion Analysis by Market Taxonomy

        18.13.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.13.2.1. By Phase

            18.13.2.2. By Type

            18.13.2.3. By Therapeutic Area

            18.13.2.4. By Test Type

    18.14. South Korea Analysis

        18.14.1. Value Proportion Analysis by Market Taxonomy

        18.14.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.14.2.1. By Phase

            18.14.2.2. By Type

            18.14.2.3. By Therapeutic Area

            18.14.2.4. By Test Type

    18.15. GCC Countries Analysis

        18.15.1. Value Proportion Analysis by Market Taxonomy

        18.15.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.15.2.1. By Phase

            18.15.2.2. By Type

            18.15.2.3. By Therapeutic Area

            18.15.2.4. By Test Type

    18.16. South Africa Analysis

        18.16.1. Value Proportion Analysis by Market Taxonomy

        18.16.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.16.2.1. By Phase

            18.16.2.2. By Type

            18.16.2.3. By Therapeutic Area

            18.16.2.4. By Test Type

    18.17. Turkey Analysis

        18.17.1. Value Proportion Analysis by Market Taxonomy

        18.17.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

            18.17.2.1. By Phase

            18.17.2.2. By Type

            18.17.2.3. By Therapeutic Area

            18.17.2.4. By Test Type

        18.17.3. Competition Landscape and Player Concentration in the Country

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies

    19.2. Market Concentration

    19.3. Market Share Analysis of Top Players

    19.4. Market Presence Analysis

        19.4.1. By Regional footprint of Players

        19.4.2. Product footprint by Players

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Competition Benchmarking

    20.3. Competition Deep Dive

        20.3.1. Covance, Inc.

        20.3.2. IQVIA

        20.3.3. Syneos Health

        20.3.4. Charles River Laboratory International

        20.3.5. ICON Plc

        20.3.6. SGS SA

        20.3.7. Toxikon

        20.3.8. Intertek Group plc

        20.3.9. Pace Analytical Services LLC

        20.3.10. PPD, INC.

21. Assumptions and Acronyms Used

22. Research Methodology

Explore Healthcare Insights

View Reports

Large Molecule Bioanalytical Testing Services Market